The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
April 30th 2025
As the cell and gene therapy pipeline expands, experts at Asembia’s AXS25 Summit emphasized the need for error-proof logistics, value-based access strategies, and coordinated reimbursement models.
Specialty Products: BriovaRx's Holistic Approach
November 28th 2012In an exclusive interview with Specialty Pharmacy Times, Albert Thigpen, Senior Vice President of Pharmacy Operations & Industry Relations at Catamaran Corporation, spoke about his distinct responsibilities surrounding the management of pharmaceutical manufacturers, Catamaran's 3 mail order pharmacies, and BriovaRx's 11 specialty pharmacies.
Read More
Higher Copays for Multiple Sclerosis Medications Contribute to Poor Patient Compliance, Outcomes
November 22nd 2012A recent study featured in the American Journal of Pharmacy Benefits examines the role of patient out-of-pocket cost on adherence to disease-modifying therapies for multiple sclerosis.
Read More
Xeljanz: Juggling a Delicate Risk-Benefit Ratio
November 16th 2012Pfizer's Xeljanz (tofacitinib) is the first Janus kinase inhibitor approved for rheumatoid arthritis and the first oral biologic within the RA class. Dina Rufo of GlobalData discusses the factors that will affect uptake of the drug.
Read More
CSPN Signs Distribution Agreement with Dara BioSciences
November 16th 2012Community Specialty Pharmacy Network, Inc (CSPN), recently announced a distribution agreement with Dara BioSciences for Soltamox (tamoxifen citrate), a nonsteroidal antiestrogen for the treatment of patients with breast cancer.
Read More
Diplomat Specialty Pharmacy Announces Executive Hire and Promotion
November 16th 2012Diplomat Specialty Pharmacy announced that Jennifer Cretu has been promoted to vice president of information technology and pharmacy executive Thomas Michaels has joined the company as vice president of sales and marketing.
Read More
UnitedHealthcare Bars Copay Coupons for Specialty Drugs
November 14th 2012According to a report by Elsevier's Business Intelligence, UnitedHealthcare has announced that pharmacies that are participating in its Designated Specialty Pharmacy network will no longer redeem manufacturer-sponsored coupons.
Read More
Sanofi Halves the Price of Zaltrap in Response to Criticism from Oncologists
November 13th 2012Sanofi slashed the price of colorectal cancer drug Zaltrap (ziv-aflibercept) in half after 2 oncologists from Memorial Sloan-Kettering Cancer Center publicly balked at the drug's $11,000 price tag in an op-ed in The New York Times.
Read More
Diplomat Specialty Pharmacy Hiring Continues as Long-Term Michigan Growth Plan Moves Forward
November 7th 2012Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy company servicing the needs of patients and physicians nationwide, is on target to meet its long-term growth plan with the announcement that it has an immediate need to fill 100 full-time jobs.
Read More
Cardinal Health Specialty Pharmacy, OncoSourceRx, Earns URAC Accreditation
November 1st 2012Cardinal Health Specialty Solutions announced today that its specialty pharmacy, OncoSourceRx, has been awarded Specialty Pharmacy Accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.
Read More
Avella Specialty Pharmacy to Distribute Soltamox
October 22nd 2012Avella Specialty Pharmacy, under an agreement with DARA BioSciences, Inc, will be a distribution source for Soltamox, the first and only FDA-approved oral liquid formulation of tamoxifen citrate for the prevention and treatment of breast cancer.
Read More
Former FDA Chief Comments on the Drug Approval Process
October 19th 2012In this Medscape One-on-One video, former FDA Commissioner and former director of the National Cancer Institute Andrew von Eschenbach, MD, suggests using adaptive trial design to test drugs rather than a stepwise approach.
Read More
The Specialty Pharmacy Pipeline: What's Next?
October 17th 2012In a session at the 2012 Academy of Managed Care Pharmacy Educational Conference, Aimee Tharaldson, PharmD, identified the top specialty drugs in the pipeline and highlighted the most recent therapeutic trends within each medication class.
Read More
Multiple Sclerosis Drug Costs Account for More Than Two-Thirds of Patients' Total Cost of Care
October 17th 2012A new study carried out by Blue Cross and Blue Shield of Minnesota and PBM Prime Therapeutics forecasts that multiple sclerosis specialty drug treatment cost will exceed $50,000 per person per year in 2016.
Read More
The American Journal of Pharmacy Benefits Video: Trends in the Specialty Pharmacy Market
October 17th 2012In this video from The American Journal of Pharmacy Benefits, Aimee Tharaldson, PharmD, discusses some of the current trends in the specialty pharmacy market and notes that the pipeline for cancer drugs is likely to be the most robust.
Read More
NIH Launches Free Database of Drugs Associated with Liver Injury
October 15th 2012A free source of evidence-based information for health care professionals and for researchers studying liver injury associated with prescription and over-the-counter drugs, herbals, and dietary supplements is now available from the National Institutes of Health.
Read More
FDA Approves Abraxane as a First-Line Treatment for Advanced Non-Small Cell Lung Cancer
October 12th 2012Celgene Corporation today announced the FDA has approved Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
Read More
FDA Approves Expanded Indication for Actemra in Rheumatoid Arthritis
October 12th 2012Genentech, Inc, a member of the Roche Group, today announced that the FDA has expanded the approved indication for Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).
Read More